Table 1.

Losartan treatment effects on ESRD by proteinuria subgroupa

Baseline Proteinuria (mg/g)LosartanPlaceboHazard Ratio (95% CI)
nEvents (Rate)nEvents (Rate)
<100032617 (16.6)33029 (28.7)0.57 (0.32 to 1.05)
1000 to 200017522 (41.3)18139 (74.6)0.54 (0.32 to 0.91)
2000 to 400015856 (132.1)18076 (173.1)0.73 (0.52 to 1.03)
≥40009252 (266.3)7150 (334.0)0.78 (0.53 to 1.15)
  • a The interaction between proteinuria stratum and treatment group was not significant (P = 0.5825). CI, confidence interval; rate, event rate per 1000 patient-years of follow-up.